Simple tweak to cervical cancer treatment cuts risk of death by 40%, say researchers
- A new treatment regime for cervical cancer reduces the risk of death by 40%, according to a large-scale study.
- Findings reveal a 40% decrease in death risk and a 35% decrease in cancer recurrence within five years.
- The Interlace Phase III trial assessed if short induction chemotherapy before chemoradiation could lower relapses and deaths in patients with locally advanced cervical cancer.
Insights by Ground AI
Does this summary seem wrong?
Coverage Details
Total News Sources0
Leaning Left3Leaning Right3Center22Last UpdatedBias Distribution79% Center
Bias Distribution
- 79% of the sources are Center
78% Center
11%
C 78%
11%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
